Wordt geladen...
Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells
BACKGROUND AND PURPOSE: Inhibition of proteasome has been emerging as a promising approach in pathway-directed cancer therapy. Bone morphogenetic protein (BMP) signalling, which is known to be regulated by the ubiquitin–proteasome pathway in osteoblasts, plays a crucial role in the suppression of ga...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group
2008
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2439517/ https://ncbi.nlm.nih.gov/pubmed/18414391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjp.2008.115 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|